A carregar...
Emerging therapies for acute myeloid leukemia: translating biology into the clinic
Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a poor outcome; overall survival is approximately 35% at two years and some subgroups have a less than 5% two-year survival. Recently, significant improvements have been made in our understanding of AML biology and genetics....
Na minha lista:
Publicado no: | JCI Insight |
---|---|
Main Authors: | , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
American Society for Clinical Investigation
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5621868/ https://ncbi.nlm.nih.gov/pubmed/28931762 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.95679 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|